

6

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Jennifer June Brown et al.

Serial No. 10/042,711

Filed: December 12, 2001

Title: BIOLOGICAL MODELS CAPABLE OF EXHIBITING  
SECONDARY DISEASE MANIFESTATIONS AND  
USEFUL FOR DEVELOPING THERAPEUTIC DRUGS  
DIAGNOSTIC PRODUCTS AND THERAPEUTIC OR  
DIAGNOSTIC PROCEDURES, METHODS OF USING  
SAME, AND CELLS, TISSUES AND ORGANS  
DERIVED THEREFROM



Group Art Unit: 1632

Examiner: Not Yet Known

527 Madison Avenue, 9th Floor  
New York, New York 10022  
December 30, 2002

**FILED BY EXPRESS MAIL**

United States Patent and Trademark Office  
P.O. Box 2327  
Arlington, Virginia 22202  
**Attention: Box Sequence**

**AMENDMENT IN RESPONSE TO NOTICE**  
**TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION – COMPLIANCE**  
**WITH REQUIREMENTS OF 37 CFR 1.821-1.825 – SEQUENCE RULES**

Dear Sirs:

In response to the Notice to Comply With Requirements for Applications containing Sequence Disclosures mailed on July 30, 2002, please amend the application as follows:

EXPRESS MAIL CERTIFICATE	
"Express Mail" Label No. EV205342210US	
Deposit Date	December 30, 2002
I hereby certify that this paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington DC 20231.	
Ronald C. Fedus Reg. No. 32,567	DEC 30 2002 Date

Jennifer June Brown et al.

Serial No. 10/042,711

Filed: December 12, 2001

Page 2 (AMENDMENT IN RESPONSE TO NOTICE TO FILE MISSING PARTS OF NON-  
PROVISIONAL APPLICATION – COMPLIANCE WITH REQUIREMENTS OF 37 CFR 1.821-1.825

– SEQUENCE RULES –

December 30, 2002)

**In the Specification:**

Please amend the specification as shown:

Please delete the paragraph on page 11, lines 19-25, and replace it with the following paragraph:

***In situ* PCR amplification and detection of HBV RNA.** Reactions were carried out according to the protocol described in Liu et al., (1997; J. Vir. 71:4079) except that HBV specific sequences for primers and probe were used. The sequences for these is as follows:

HBV A: 5'-TGCCTGAGTGC(TA)GTATG-3' (SEQ ID NO: 1)

HBV B: 5'-TAGGAGGCTGTAGGCAT-3' (SEQ ID NO: 2)

HB Probe: 5'-TTTATAAGGGTCGATGTCCAT-3' (SEQ ID NO: 3)

**ENZ-57(CIP)(C)**

Jennifer June Brown et al.

Serial No. 10/042,711

Filed: December 12, 2001

Page 3 (AMENDMENT IN RESPONSE TO NOTICE TO FILE MISSING PARTS OF NON-  
PROVISIONAL APPLICATION – COMPLIANCE WITH REQUIREMENTS OF 37 CFR 1.821-1.825

– SEQUENCE RULES –


December 30, 2002)

### REMARKS

No fee is believed due in connection with this Communication or the documents or items submitted herewith. If any fee or fees are due, however, the Patent and Trademark Office is hereby authorized to charge the amount of any such fee to Deposit Account 05-1135, or to credit any overpayment thereto; and applicants hereby petition for any needed extension of time...

The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

Respectfully submitted,



Ronald C. Fedus

Registration No. 32,567

Attorney for Applicants

Dated: December 30, 2002

ENZO THERAPEUTICS, INC.

c/o Enzo Biochem, Inc.

527 Madison Avenue (9<sup>th</sup> Fl.)

New York, New York 10022

(212) 583-0100

Amendment.re.sequence.rules.123002.Enz57(CIP)(C)

**ENZ-57(CIP)(C)**

Jennifer June Brown et al.

Serial No. 10/042,711

Filed: December 12, 2001

Page 4 (AMENDMENT IN RESPONSE TO NOTICE TO FILE MISSING PARTS OF NON-  
PROVISIONAL APPLICATION – COMPLIANCE WITH REQUIREMENTS OF 37 CFR 1.821-1.825

– SEQUENCE RULES –

December 30, 2002)

**MARKED UP VERSION ATTACHED TO AMENDMENT IN**

**SERIAL NO. 10/042,711**

Marked up version of the paragraph starting at page 11, lines 19-25, is below:

***In situ* PCR amplification and detection of HBV RNA.** Reactions were carried out according to the protocol described in Liu et al., (1997; J. Vir. 71:4079) except that HBV specific sequences for primers and probe were used. The sequences for these is as follows:

HBV A: 5'-TGCCTGAGTGC(TA)GTATG-3' (SEQ ID NO: 1)

HBV B: 5'-TAGGAGGCTGTAGGCAT-3' (SEQ ID NO: 2)

HB Probe: 5'-TTTATAAGGGTCGATGTCCAT-3' (SEQ ID NO: 3)

**ENZ-57(CIP)(C)**